Published in Drug Week, March 31st, 2006
"We performed a phase II study to assess feasibility, pain relief, and toxicity of a tetracaine-based oral gel in the treatment of RT-induced mucositis. Fifty patients treated with RT for head-and-neck cancer with clinical evidence of acute oral mucositis of grade 2:2 were scheduled to receive the tetracaine gel. A questionnaire evaluating the effect of the gel was given to all subjects," scientists in Italy reported.
"In 38 patients (79.2%), a reduction in oral cavity pain was reported. Thirty-four patients (82.9%) reported no side effect....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.